Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Solutions to Slash 25% of Jobs; Future of Proteomics Effort Uncertain

NEW YORK, Sept. 7 – Proteomics and microarray developer Genomic Solutions said on Friday it plans to cut 25 percent of its workforce and restructure its business to help it become profitable by the first quarter of next year.

The company said in a statement that the restructuring includes the closing of an R&D and manufacturing facility in Lansing, Michigan. Jobs associated with that space will be transplanted to the company’s headquarters in Ann Arbor.

Jobs in Michigan and in Genomic Solutions’ offices in the UK will be eliminated by the end of the fourth quarter this year.

The company said its proteomic contract research business will either be spun out to an internal management group as a stand-alone business with Genomic Solutions as a minority shareholder, or will be sold outright.

Genomic Solutions also said it intends to retain chemical, reagent, and accessory manufacturing operations that share facilities with the proteomic contract research center. The company will continue to offer genomic research services in its existing in-house genomic laboratory.

“We are taking steps now to accelerate achievement of Genomic Solutions' financial performance goals,” Jeffrey S. Williams, the firm’s president and chief executive officer, said in the statement. “It is more than simply cutting costs--it is a fundamental restructuring of all of our available resources to further build our position as one of the leading suppliers of DNA microarray and proteomic systems in the life sciences marketplace.”

Separately on Friday, Genomic Solutions said it plans to purchase privately held Cartesian Technologies in a cash and stock deal that the struggling company hopes will buttress its foothold in the automation tools market.

Terms of the deal call for Genomic Solutions to issue 6.8 million shares of common stock, options to buy 449,319 shares of common stock and $2.5 million in cash.

“Enhanced revenue and cost reduction opportunities, plus the inherent product cross-selling opportunities, make this acquisition a timely, ideal fit for Genomic Solutions,” Williams said in a separate statement.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.